C-TLNEInsilico Medicine
generative AI, automation, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-TLNE
C-TLNEC-TLNEgenerative AI, automation, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Insilico Medicine generative AI, automation, drug discovery
Insilico Medicine aims to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence. The site describes AI-driven target discovery, molecule generation, therapeutic pipeline programs, and Pharma.ai software products including PandaOmics, Chemistry42, inClinico, and Science42:DORA. Its pipeline includes programs for fibrotic diseases, cancer, inflammatory bowel disease, chronic kidney disease, COVID-19, and other indications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Insilico Medicine — Translational · Bottom quartile. Derived deterministically from 56 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (3 programs at…
Source: Deterministic